Atlas Trials

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Clinical trial NCT04943679 · UNKNOWN

Trial details

NCT number
NCT04943679
Sponsor
Shanghai Zhongshan Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
Hepatocellular Carcinoma
Start date
2021-06-15
Primary completion
2024-12-31
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.